Frank Czerwiec

Frank has been a medical researcher for over 30 years; motivated to find solutions for patients with unmet medical needs. Working in industry for the past 24 years, as Chief Medical Officer of Goldfinch Bio he recently helped build the Clinical Development, Regulatory and Medical Affairs groups supporting the launch of several early phase clinical programs. With progressively increasing responsibilities, culminating as VP of Clinical Development at Otsuka Pharmaceutical Development & Commercialization, Frank’s team was instrumental in securing tolvaptan’s global approvals for the treatment of hyponatremia (Samsca®) and autosomal dominant polycystic kidney disease (Jinarc/Jynarque®).

Frank graduated from the University of Miami School of Medicine’s Combined Clinician Scientist program with both a PhD in Biochemistry & Molecular Biology and an MD followed by an American Board of Internal Medicine Research Pathway residency. He completed NIH-NICHD/NIDDK Adult Endocrinology Fellowship where he was first exposed to formal clinical investigation serving patients having rare medical conditions like congenital adrenal hyperplasia, hypercalcuric hypoparathyroidism, Cushing disease/syndrome and McCune-Albright syndrome. There he also opened an investigator-initiated IND for dihydrotestosterone treatment of male pseudohermaphroiditism (5-alpha reductase deficiency). After the NIH, Frank’s focus shifted to endocrine and cardio-renal conditions, where he sought innovative solutions to clinical problems involving patients and families wherever possible.